For instance, at the time of the TARGET-T2D study, SGLT2 inhibitors were not approved for use at General medicine clinics and hence, patients who were indicated for treatment would need to be referred to Endocrinologists. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.